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Abstract
Background: Exportin 1 (XPO1) is a well-characterized nuclear export protein whose expression is up-regulated
in many types of cancers and functions to transport key tumor suppressor proteins (TSPs) from the nucleus.
Karyopharm Therapeutics has developed a series of small-molecule Selective Inhibitor of Nuclear Export (SINE)
compounds, which have been shown to block XPO1 function both in vitro and in vivo. The drug candidate,
selinexor (KPT-330), is currently in Phase-II/IIb clinical trials for treatment of both hematologic and solid tumors.
The present study sought to decipher the mechanisms that render cells either sensitive or resistant to treatment
with SINE compounds, represented by KPT-185, an early analogue of KPT-330.
Methods: Using the human fibrosarcoma HT1080 cell line, resistance to SINE was acquired over a period of
10 months of constant incubation with increasing concentration of KPT-185. Cell viability was assayed by MTT.
Immunofluorescence was used to compare nuclear export of TSPs. Fluorescence activated cell sorting (FACS),
quantitative polymerase chain reaction (qPCR), and immunoblots were used to measure effects on cell cycle, gene
expression, and cell death. RNA from naïve and drug treated parental and resistant cells was analyzed by Affymetrix
microarrays.
Results: Treatment of HT1080 cells with gradually increasing concentrations of SINE resulted in > 100 fold
decrease in sensitivity to SINE cytotoxicity. Resistant cells displayed prolonged cell cycle, reduced nuclear
accumulation of TSPs, and similar changes in protein expression compared to parental cells, however the
magnitude of the protein expression changes were more significant in parental cells. Microarray analyses
comparing parental to resistant cells indicate that a number of key signaling pathways were altered in resistant
cells including expression changes in genes involved in adhesion, apoptosis, and inflammation. While the patterns
of changes in transcription following drug treatment are similar in parental and resistant cells, the extent of response
was more robust in the parental cells.
Conclusions: These results suggest that SINE resistance is conferred by alterations in signaling pathways downstream of
XPO1 inhibition. Modulation of these pathways could potentially overcome the resistance to nuclear export inhibitors.
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Background
One of the hallmarks of cancer is the inactivation of tumor
suppressor proteins (TSPs) resulting from their mislocali-
zation within the cell. Exclusion of TSPs from the nucleus
prevents them from activating cell cycle checkpoints, indu-
cing cell cycle arrest, and initiating apoptosis resulting in
unrestricted tumor cell propagation. Exportin 1 (XPO1,
also known as CRM1) is a member of the karyopherin-β
protein family that is responsible for a majority of the
nuclear-cytoplasmic protein shuttling [reviewed in [1]].
XPO1 primarily functions as a nuclear export protein
whose expression is highly up-regulated in many types of
aggressive cancers including glioblastoma [2], ovarian [3],
osteosarcoma [4], pancreatic [5], cervical [6], renal [7],
metastatic melanoma [8], mantle cell lymphoma [9], acute
myeloid leukemia [10], multiple myeloma [11, 12], and
leukemia [13] and is the sole transporter of the key TSPs
and regulatory proteins p53 [14, 15], p73 [16], p21CIP [17],
p27KIP1 [18], FOXO [19], IĸB [20], Rb [21], and BRCA1
[22], as well as >200 other cargoes [23]. In conjunction
with RanGTP and RanBP3, nuclear XPO1 binds to the
leucine-rich nuclear export signal (NES) of a particular
cargo protein and transports it through the nuclear pore
complex to the cytoplasm. Then RanGTP is hydrolyzed to
RanGDP through combined action of RanGAP and
RanBP1 resulting in the dissociation of the XPO1/protein
complex [reviewed in [24]].
Leptomycin B (LMB) [25] is a well-characterized nat-
ural small molecule inhibitor of XPO1 [26] which forms
an irreversible covalent bond to Cys528 in the XPO1
NES binding pocket thereby preventing the interaction
between XPO1 and its cargo [27]. LMB, however, failed
as a therapy due to poor tolerability in the clinic [28].
Subsequently, synthetic inhibitors of XPO1 have been
developed including the LMB analog KOS-2464 [17],
the maleimide CBS9106 [29], a series of N-azolylacrylates
[30], and Karyopharm SINE compounds. SINE com-
pounds covalently bind to Cys528 of XPO1 and appear
to be released from the protein in a slowly reversible
manner [31–33]. The effect of SINE compounds on a
variety of cancer types has been extensively evaluated
in preclinical settings, including mantle cell lymphoma
[9, 34], non-Hodgkin’s lymphoma [35], multiple mye-
loma [11, 12], leukemia [32, 36], acute myeloid
leukemia [10, 13, 37], chronic lymphocytic leukemia
[31, 38], triple-negative breast cancer [39], renal cell
carcinoma [7, 40], pancreatic cancer [16, 41], melanoma
[42, 43], non-small cell lung cancer [44, 45], glioblastoma
[46], hepatocellular carcinoma [47], esophageal squa-
mous cell carcinoma [48], and prostate cancer [49, 50].
The oral drug candidate, selinexor (KPT-330), is
currently in both phase 1 and phase 2 clinical trials
(Clinicaltrials.gov) for the treatment of hematological
as well as solid tumors. Selinexor is well tolerated and
shows therapeutic promise (Phase 1 clinical trial manu-
scripts in preparation).
Although many drugs are initially effective in killing
cancer cells, the likelihood for a tumor to develop re-
sistance to a particular drug is a reality that must be an-
ticipated. Many mechanisms exist which may render a
cell resistant to drug treatment, both intrinsic and ac-
quired, such as chemical inactivation of the drug,
changes in DNA repair mechanisms, delayed apoptosis,
increased drug efflux, down-regulation of the drug tar-
get or pro-apoptotic factors, changes in drug metabol-
ism, and drug target modifications [reviewed in [51]],
as well as alterations in the intracellular localization of
a particular protein(s) [17]. In an effort to predict po-
tential mechanisms of resistance that may arise during
clinical treatment with SINE compounds, we have
established SINE compound-resistant cells from the
parental SINE compound-sensitive HT1080 fibrosar-
coma (wt p53) cell line [52]. The response of resistant
and parental cells to treatment with SINE compounds
was compared by examining changes in proliferation,
cell cycle phases, protein localization and expression,
and gene expression profiles. In addition, the DNA se-
quence of the XPO1 cargo-binding pocket, the ability
of XPO1 to bind drug, as well as drug efflux activity
was evaluated in parental and resistant cells. The findings
presented in this study indicate that developing resistance
to SINE compounds is a prolonged process that involves
modulating the expression of genes downstream of XPO1
inhibition that are involved in pathways such as inflamma-
tion, cell adhesion, and apoptosis, and provide guidance
for future studies to test the inhibition of these pathways
in combination with selinexor in order to overcome
resistance.
Methods
Cell culture and reagents
HT1080 cell lines (ATCC) were cultured in EMEM,
Neo-NHEK (Lonza) was cultured in KGM-Gold, HaCAT
(AddexBio) was cultured in DMEM, and leukocytes were
isolated from healthy donor whole blood by the Buffer
EL (Erythrocyte Lysis Buffer, Qiagen) method and cul-
tured ex vivo in RPMI. Media were supplemented with
10 % heat-inactivated fetal bovine serum (FBS, Gibco),
100 units/mL penicillin, 100 μg/mL streptomycin (Gibco),
and 1× GlutaMAX (Gibco), and maintained in a humidi-
fied incubator at 37 °C in 5 % CO2. Resistant HT1080 cells
were initiated in the presence of 5 nM KPT-185 and
over the course of approximately 10 months the con-
centration was gradually escalated to 600 nM. The
XPO1 SINE compounds KPT-185, KPT-251, and KPT-
330 were synthesized at Karyopharm Therapeutics, Inc.
(Newton, MA).
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Clonogenic survival assay
HT1080 parental and resistant cells were plated at 5000
cells/well in 12 well plates (Cell Treat). The following
day cells were treated with either DMSO (Sigma) or with
KPT-185 (0, 3.7, 12.3, 111, 333, or 1000 nM for generation
of resistance, or 1 μM to evaluate resistance). On days 0,
4, 6, and 8 cells were fixed and stained with Gentian Violet
(RICCA Chemical Company) and imaged with a digital
camera (Sony Cybershot).
MTT assay
Cells from log phase cultures were seeded in 96-well
flat-bottom culture plates. Escalating concentrations of
KPT-185, KPT-330, KPT-251, or leptomycin B (LMB)
were added to the wells and incubated at 37 °C in a 5 %
humidified CO2 incubator for 72 hours (in triplicate).
The CellTiter-Fluor Cell Viability Assay (Promega) was
performed as instructed by the manufacturer. The
whole procedure was repeated three times. The inhibi-
tory rate of cell growth was calculated using the for-
mula: % Growth inhibition = (1− OD extract treated)/
OD negative control × 100) [53].
Flow Cytometry
Cell cycle profile analysis was performed using the BrdU
Flow Kit (BD Pharmingen) according to the manufac-
ture’s protocol. Briefly, HT1080 parental and resistant
cells were plated in 6 well plates at 500,000 cells/well.
Cells were treated with either DMSO or 600 nM KPT-
185. Prior to harvesting, HT1080 parental cells were
incubated with 10 μM BrdU for 2 hours while HT1080
resistant cells were incubated with 10 μM BrdU for
4 hours. Cells were fixed and stained for BrdU and 7-
AAD according to the manufacturer’s protocol. Cells
were then analyzed on a BD LSRFortessa (BD Biosci-
ences) at the Dana Farber Cancer Institute (Boston, MA)
and the data was subsequently analyzed using FCS Ex-
press 4 software (De Novo Software).
Immunofluorescence
HT1080 parental and resistant cells were plated on glass
coverslips (BioCoat, BD Biosciences) at 500,000 cells/well
in 6 well plates and grown overnight. Cells were treated
with 1 μM KPT −185 for either 4 hours to detect p53 and
IkB or for 24 hours to detect p21, p27, FOXO-1, and
PP2A. After treatment, coverslips were washed with 1×
PBS (phosphate buffered saline) then fixed in either 3 %
paraformaldehyde buffer (3 % paraformaldehyde/2 %
sucrose/1× PBS) or 100 % ice-cold methanol for 15 min
then washed with 1× PBS. Cells were permeabilized
with 0.1 % Triton X-100/1 % BSA/1× PBS (PFA fixation)
or 0.1 % Tween 20/0.3 M glycine/1 % BSA/1× PBS
(Methanol fixation) for at least 30 minutes. After washing
3 times with 1× PBS, cells were stained overnight with the
corresponding antibodies listed above diluted in 1%BSA/
1× PBS. Protein signal was detected with species specific
Alexa Fluor 488 secondary antibodies (Invitrogen)
while DNA was stained with DAPI (Invitrogen). Pro-
tein localization was visualized with a Nikon Eclipse Ti
inverted fluorescence microscope (Nikon) and mono-
chrome camera (ANDOR).
Western blot
HT1080 parental and resistant cells were plated at
375,000 cells/well in 6 well plates and treated with ei-
ther DMSO (0) or 0.03, 0.1, 0.6, 1, or 3 μM KPT-185
for 24 hours prior to collection by trypsinization. Pro-
teins were extracted from cells in Pierce RIPA buffer
(Thermo Scientific) supplemented with phosphatase
and protease inhibitors (Roche), quantified by the
Pierce BCA Protein Assay Kit (Thermo Scientific), and
normalized such that for each sample 10 μg of total
protein was loaded per lane. Proteins were separated by
loading on Novex NuPAGE 4–12 % Bis-Tris Gels (Life
Technologies) and transferring to nitrocellulose with
the Novex iBlot Gel Transfer Stacks (Life Technolo-
gies). The following primary antibodies were used for
immunoblot analysis: XPO1 (Santa Cruz), p53 (Santa
Cruz), p21 (Abcam), PARP (Cell Signaling), Caspase 3
(Abcam), cleaved Caspase 3 (Cell Signaling), Mcl-1
(Santa Cruz), p-pRb (Cell Signaling), pRb (Cell Signaling),
and β-actin (Santa Cruz). Protein signals were detected
with infrared linked species-specific secondary antibodies
(LI-COR Biosciences). Western blot images were detected
with the ODYSSEY Infrared Imaging System (LI-COR
Biosciences).
Microarray analysis
HT1080 parental and resistant cells were grown for
8 hours in either control DMSO (untreated) or 600 nM
KPT-185 (treated) and each condition was prepared in
triplicate. Cells were harvested and total RNA was ex-
tracted from the 12 independent preparations (3 repeti-
tions of each sample) from untreated parental,
untreated resistant, treated parental, and treated resist-
ant. The RNA was submitted to Asuragen and was then
quality assured and reverse transcribed to cDNA. Micro-
array data was collected at Asuragen using GeneChip
Affymetrix HuGene10stv1_Hs_ENTREZG_desc array, ac-
cording to standardized operating procedures. Microarray
data was then interrogated with the MetaCore software
suite from Thomson Reuters.
Quantitative real-time PCR
Cells were cultured with vehicle or KPT-185 for 4 or
24 hours, then cells were collected and total RNA was
purified using the QIAmp RNA Blood Mini Kit (Qiagen),
including treatment with DNAse (Qiagen). cDNA was
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reversed transcribed from the purified RNA using the
High Capacity cDNA Reverse Transcriptase Kit (Life
Technologies). Quantitative real-time PCR was performed
with Taqman probes for a subset of genes (see Table 7)
and GAPDH (Life Technologies) using the ViiA 7 Real-
Time PCR System (Life Technologies).
Results
Resistance to drugs by cancer cells is a major obstacle in
cancer therapy. In an effort to evaluate the ability of a
cancer cell to overcome SINE compound-mediated can-
cer cell death, we sought to create a SINE compound-
resistant cancer cell line (Fig. 1). Due to its wt p53
status, ease of cultivation, and sensitivity to SINE com-
pounds, the HT1080 fibrosarcoma cell line was chosen
for this endeavor. In order to determine the starting
concentration of SINE compound to generate the resist-
ant cells, HT1080 cells were initially grown in increasing
concentrations of the SINE compound KPT-185 for
8 days and evaluated for growth by the clonal growth
assay (Fig. 1a). Cells were able to grow in KPT-185 at
concentrations up to 12.3 nM but not at 111 nM (evalu-
ated by gentian violet staining). Consequently, 5 nM
KPT-185 was selected as the initial concentration for the
selection of the resistant cells. Over the course of ap-
proximately 10 months, the cells were cultured in the
presence of gradually escalating concentrations of KPT-
185 until the concentration reached 600 nM. It was at
this point that the cells were considered “resistant” and
evaluated for their response to KPT-185 treatment com-
pared to sensitive, parental HT1080 cells.
We then compared the effects of SINE compounds on
the viability of resistant versus parental cells (Fig. 1b).
An approximately 130-fold reduction in sensitivity was
observed for KPT-185 (IC50 of 0.013 μM in parental cells
compared with an IC50 of 1.7 μM in resistant cells). Next
we determined whether resistance was specific for KPT-
185 or would also be observed with two additional,
structurally related SINE compounds, KPT-330 and
KPT-251. An approximately 33-fold reduction was mea-
sured for KPT-330 (0.074 μM compared to 2.4 μM in
parental and resistant cells, respectively) and for KPT-
251 an ~14-fold difference in sensitivity was observed
(IC50 of 0.066 μM compared to 0.93 μM in parental and
resistant cells, respectively). This data suggests that the
KPT-185 resistant cells are also resistant to additional
analogues of this class of SINE compounds. Resistant
cells were also slightly less sensitive to LMB, with an
IC50 of 0.0014 μM compared to 0.0003 μM for parental
cells.
Next, we sought to characterize the differences in re-
sponse to treatment with SINE compounds between
parental and resistant cells. We first tested the cells by the
clonal growth assay. Parental and resistant cells were
incubated with 1 μM of KPT-185 for 8 days and then eval-
uated for survival and cell division (Fig. 1c). Parental cells
did not survive in KPT-185 whereas resistant cells were
able to proliferate in culture in the presence of 1 μM KPT-
185. Next, we tested by Fluorescence Activated Cell Sort-
ing (FACS) the effects of KPT-185 on the cell cycle
(Fig. 1d). Cells were incubated with or without 0.6 μM
KPT-185 and their cell cycle distribution profile was eval-
uated daily. The results show that parental and resistant
cells have different cell cycle profiles when incubated with
KPT-185. Parental cells show a dramatic (≥10-fold) reduc-
tion in S-phase and an approximately 3-fold increase in
G2/M phases while resistant cells show a less marked re-
duction in S-phase (2- to 4-fold) with little change in G2/
M. Taken together, these data demonstrate that resistant
cells, unlike parental cells, are much less likely to undergo
cell cycle arrest at G2/M and are able to survive and con-
tinue to proliferate, albeit more slowly, in the presence of
KPT-185.
Previous studies have shown that XPO1 inhibition
with SINE compounds induces nuclear accumulation of
its cargoes, which include most of the major tumor
suppressor and cell cycle regulatory proteins [reviewed
in [54–56]]. The ability of SINE compounds to force
nuclear retention of XPO1 cargoes was compared in
parental and resistant cells (Fig. 2). Both cell lines were
treated with either control (DMSO) or 1 μM KPT-185
and evaluated by immunofluorescent analysis for the
subcellular localization of IkB and p53 after 4 hours of
treatment, and for p21, p27, FOXO-1, and PP2A after
24 hours of treatment. In parental cells, KPT-185 forced
effective nuclear localization of all six cargoes examined.
However, in the resistant cells treated with KPT-185,
the nuclear localization of the six cargoes was less in-
tense than in parental cells, with certain cargoes retain-
ing cytoplasmic localization, particularly for IkB, p27,
FOXO-1, and PP2A. These data indicate that SINE
compounds are less effective at inducing nuclear accu-
mulation of XPO1 cargoes in resistant cells.
In addition to increasing nuclear retention of XPO1
cargoes, SINE compounds also modulate the expression
levels of several key regulatory proteins [9, 10, 37, 42].
In order to compare the steady state protein expression
profiles of regulatory proteins, both parental and resist-
ant cells were treated with increasing concentrations of
KPT-185 up to 3 μM for 24 hours followed by immuno-
blot analysis (Fig. 3). For all proteins evaluated, the ob-
served expression changes occurred at lower compound
concentrations in parental cells compared to resistant
cells. The levels of XPO1 protein was substantially de-
creased in parental cells treated with 0.03 μM KPT-185
and decreased dramatically at 0.1 μM whereas in resistant
cells a comparable level of reduced expression was not
reached until treatment with 3 μM KPT-185. Induction of
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the expression of the TSPs p53 and p21 also occurred at
lower KPT-185 concentrations in parental than resistant
cells. Induction of apoptosis, as indicated by cleavage of
PARP and Caspase 3, was observed at 0.6 μM KPT-185 in
parental cells but was not detected in resistant cells until
treatment with 3 μM KPT-185. In line with the induction
of apoptosis with SINE compound treatment, a greater de-
crease in the expression of the pro-survival protein Mcl-1
was detected in parental cells compared to resistant cells.
Likewise, dephosphorylation of the inactive pRb form, in
response to KPT-185, occurred at lower KPT-185 concen-
trations in parental cells compared to resistant cells. Taken
together, SINE compound-mediated changes in the levels
of key regulatory proteins indicate that cell cycle arrest
and apoptosis are initiated at lower drug concentrations in
parental cells than in resistant cells.
Recently, Neggers and colleagues reported that the
sensitivity of T-cell lymphoma to SINE compounds was
reduced by more than 250-fold by a knock-in experiment
when cysteine 528, the residue that binds SINE
(See figure on previous page.)
Fig. 1 Generation of SINE compound-resistant HT1080 cells. a HT1080 parental cells grown in 0, 3.7, 12.3, 111, 333, and 1000 nM KPT-185 in an 8 day
clonal assay (stained with gentian violet) for the selection of the KPT concentration to initiate generation of the resistant cell line. b IC50 values for
parental and resistant cells treated with KPT-185, KPT-330, and LMB, determined in an MTT assay. c HT1080 parental and resistant cells grown in 1 μM
KPT-185 in the 8 day clonal growth assay (stained with gentian violet). d FACS cell-cycle analysis of HT1080 parental and resistant cells treated with 0
or 600 nM KPT-185 for 1–3 days
Fig. 2 SINE compound-induced nuclear localization is impaired in resistant HT1080 cells. Parental and resistant cells were treated with either
DMSO or 1 μM KPT-185 and then evaluated by immunofluorescence for the subcellular localization of IkB, p53, p21, p27, FOXO-1, and PP2A
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compounds, as well as LMB, was mutated to serine on
XPO1 [57]. To determine whether resistance in HT1080
was the result of mutations in cysteine 528, DNA from re-
sistant and parental cells was extracted and the XPO1
gene was sequenced. The sequence of the XPO1 cargo-
binding pocket was identical between parental and resist-
ant cells (data not shown). Therefore, resistance of
HT1080 cells to KPT-185 is not associated with mutations
in the SINE compounds binding site of XPO1.
To test whether there was an alteration in drug-target
interaction in resistant cells, both parental and resistant
cells were tested in an XPO1 occupancy assay (manu-
script in preparation). In this assay, cells were treated
with serially increasing amounts of SINE compound
followed by the addition of biotinylated LMB and then
evaluated for the amount of XPO1 bound to drug com-
pared to that bound to biotinylated LMB. The results
from this assay showed that resistant and parental cells
had the same XPO1 occupancy values (data not shown).
This indicates that reduction of the drug-target inter-
action was not the means of conferring resistance in the
HT1080 cells.
Next, we sought to determine whether resistance was the
result of the activation of common multidrug resistance
mechanisms. Parental and resistant cells were incubated
with Cyclosporin A or Verapamil, which are the competi-
tive and non-competitive inhibitors of P-Glycoprotein, the
multidrug resistance MDR1 gene product, and the multi-
drug resistance associated proteins (MRP). Both proteins
are members of the superfamily of ATP-binding cassette
(ABC) transporters. Calcein A was used as a substrate to
quantify the transporter activity. The analyses revealed
similar accumulation of calcein A in untreated and treated
parental and resistant cells (not shown). This indicated
that resistant cells did not gain activation of these multi-
drug resistance transporters. Taken together, the above re-
sults suggest that development of resistance to SINE
compounds was not the result of mutations in the cargo
binding pocket of XPO1 or other modification that re-
duced drug-target binding, or activation of a common
multidrug resistance mechanism that exclude drug from
the cell cytoplasm. Therefore, resistance is likely achieved
through modulation of an inhibitory pathway(s) down-
stream of XPO1 inhibition.
In an effort to identify SINE compound resistance
mechanisms exploited by HT1080 cells, we used gene ex-
pression profiling analysis to compare expression patterns
between parental and resistant cells. Previous observations
showed that XPO1 inhibition can be detected as early as
30 minutes following SINE compound treatment with
Fig. 3 SINE compound-mediated effects on protein expression in HT1080 parental versus resistant cells show differential dose–response. Parental
and resistant cells were treated with 0, 0.03, 0.1, 0.6, 1, and 3 μM KPT-185 for 24 hours and then evaluated by immunoblot analysis for the expres-
sion of XPO1, p53, p21, full-length (FL) and cleaved (Cl) PARP, full-length and cleaved Caspase 3, Mcl-1, p-pRb, pRb, and actin
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maximal cargo retention in the nucleus occurring between
4 and 8 hours following treatment. To allow for adequate
nuclear accumulation of XPO1 cargoes and the initiation
of gene transcription we chose to harvest the cells for ana-
lysis following 8 hours of drug treatment.
In order to identify mechanisms associated with resist-
ance to KPT-185, the gene expression profiles between re-
sistant and parental cells were compared at baseline (prior
to drug treatment). In addition, the mechanism of drug
action and how it changes when resistance is obtained
was revealed when we also compared the differential tran-
scriptional response of parental and resistant cells to drug
treatment.
Using a fold shift cut-off of +/− 1.5 fold change, analysis
of the microarray data with the Metacore program identi-
fied the following functional gene groups to be the most
differentially regulated between untreated resistant and
untreated parental cells: cell adhesion (Table 1, where red
= increased in resistant, blue = decreased in resistant, color
intensity corresponds to fold change magnitude), apop-
tosis (Table 2), and inflammation (Table 3). The cell adhe-
sion group had the highest number of genes that were
differentially expressed between untreated resistant and
parental cells (80 genes, Table 1), followed by inflamma-
tion (63 genes, Table 3), and then apoptosis (37 genes,
Table 2). Although three functional groups were identified,
the expression patterns of several genes were found to
overlap in these groups. For example, chemokine (C-C
motif) ligand 2 (CCL2) was the most differentially
expressed gene in resistant versus parental cells (13.92
fold) and was identified by the Metacore program to be
associated with both cell adhesion and inflammation path-
ways, while triggering receptor expressed on myeloid cells
1 (TREM1) had the second highest level of differential ex-
pression in resistant versus parental cells (6.89 fold) and
was identified in both apoptosis and inflammation related
pathways. Integrin, alpha 11 (ITGA11) was the most
down-regulated gene in resistant versus parental cells
(−4.12 fold) and was identified in both cell adhesion and
apoptosis related pathways, while phospholipase A2,
group IVA (cytosolic, calcium-dependent) (PLAG42A)
was one of the most down-regulated genes in resistant
versus parental cells (−3.67 fold) and was identified in all
three pathways. The modulation of the expression of these
genes known to be involved in these three functional
groups reinforces the likelihood that resistance is not con-
ferred by alterations in one single pathway but instead by
the combined effect of multiple pathways.
We next sought to investigate the differential gene
expression in response to drug treatment in parental sen-
sitive compared to resistant cells. For this analysis, expres-
sion patterns in the parental and resistant cells at baseline
(untreated) were compared to their respective SINE com-
pound treated counterparts to generate lists of genes that
are at least 1.5 fold up- and down-regulated in each cell
line in response to SINE compound treatment. Pathway
analysis comparing these lists found that the majority of
gene transcription changes for both comparisons were
part of one of three main categories, 1) apoptosis and au-
tophagy (Table 4, Fig. 4a), 2) proliferation (Table 5, Fig. 4b),
and 3) cell cycle and cytoskeleton (Table 6, Fig. 4c). Com-
parison of the response to drug treatment in parental and
resistant cells for genes with changes of 1.5 fold or greater
showed that, in general, for both the apoptosis and au-
tophagy and proliferation categories, more genes were up-
regulated in response to drug treatment in both parental
and resistant cells than down-regulated, whereas in the
cell cycle and cytoskeleton category more genes were
down-regulated in response to drug treatment in both
parental and resistant cells.
In the apoptosis and autophagy category, treated par-
ental cells had more differentially expressed genes (≥1.5-
fold change) than treated resistant cells, with 33 genes
up-regulated in parental cells compared to 31 genes re-
sistant cells, and 24 genes down-regulated in parental
cells compared to 14 genes resistant cells (Table 4). In
the proliferation category, parental cells again had more
differentially expressed genes than resistant cells in re-
sponse to drug treatment, with 23 genes up-regulated in
parental cells compared to 16 genes in resistant cells, and
7 genes down-regulated in parental cells compared to 4
genes in resistant cells (Table 5). Lastly, in the cell cycle
and cytoskeleton category, 25 genes were up-regulated in
parental cells compared to 26 genes in resistant cells,
while 97 genes were down-regulated in parental cells com-
pared to 83 genes in resistant cells (Table 6).
Overall, drug treatment induced changes in gene expres-
sion in the same direction in both parental and resistant
cells with a few exceptions. In the apoptosis and autophagy
category, inhibitor of DNA binding 2, dominant negative
helix-loop-helix protein (ID2) was up-regulated in parental
cells (1.79 fold) with no change in resistant cells (−1.08
fold), whereas in all 3 categories early growth response 1
(EGR1) was up-regulated in resistant cells (1.54 fold) with
no change in parental cells (−1.01 fold), and interleukin 1,
beta (IL1B) was down-regulated in parental cells (−1.56
fold) with no change in resistant cells (1.06 fold). These re-
sults suggest that parental cells had a more robust tran-
scriptional response to drug treatment than resistant cells.
Next, microarray quadrant analysis was used to plot the
expression changes in response to drug treatment between
parental and resistant cells for each category (Fig. 4). Fold-
change values for genes found to be at least 1.5 fold up-
or down-regulated in resistant cells were plotted on the
y-axis while fold-change values for genes found to be at
least 1.5 fold up- or down-regulated in parental cells
were plotted on the x-axis. In this visualization, any genes
falling on a diagonal line with a slope of 1 and intercept
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Table 1 MetaCore analysis of fold changes in expression of cell adhesion-related genes in SINE compound-resistant versus parental cells
pre-treatment
FDR = Benjamini-Hochberg False Discovery Rate. Red = positive, blue = negative, color intensity corresponds to fold change magnitude
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of zero demonstrate perfect correlation between the
two cell lines whereas genes that fall significantly above
or below the diagonal show differential response be-
tween resistant and parental cells. Most of the genes
clustered along the diagonal in the top right and bot-
tom left quadrants of the apoptosis and autophagy
(Fig. 4a), proliferation (Fig. 4b), and cell cycle and cyto-
skeleton (Fig. 4c) categories demonstrating the ten-
dency for the genes in these categories to follow the
same trend in expression in response to drug treatment
in both parental and resistant cells. A few genes, how-
ever, did not fall along the diagonal indicating their ex-
pression to be differentially affected by drug treatment
in one cell type compared to the other. For example, in
the apoptosis and autophagy category, nerve growth
factor receptor (NGFR) induction was similar in both
parental and resistant cells, while tumor protein p53 in-
ducible nuclear protein 1 (TP53INP1) and baculoviral
Table 2 MetaCore analysis of fold changes in expression of apoptosis-related genes in SINE compound-resistant versus parental cells
pretreatment
FDR = Benjamini-Hochberg False Discovery Rate. Red = positive, blue = negative, color intensity corresponds to fold change magnitude
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Table 3 MetaCore analysis of fold changes in inflammation-related genes in SINE compound-resistant versus parental cells pre-
treatment
FDR = Benjamini-Hochberg False Discovery Rate. Red = positive, blue = negative, color intensity corresponds to fold change magnitude
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Table 4 MetaCore analysis of fold changes in expression of apoptosis and autophagy-related genes in SINE compound-resistant ver-
sus parental cells post-treatment
FDR = Benjamini-Hochberg False Discovery Rate. Red = positive, blue = negative, color intensity corresponds to fold change magnitude
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Fig. 4 (See legend on next page.)
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IAP repeat containing 3 (BIRC3) were both more highly
expressed in parental compared to resistant cells (Fig. 4a).
In the proliferation category, BTG family, member 2
(BTG2) was more highly expressed in parental cells,
endothelin 1 (END1) was more highly expressed in resist-
ant cells, and KIT ligand (KITLG) was down-regulated in
resistant cells (Fig. 4b). Lastly, in the cell cycle and cyto-
skeleton category, piccolo presynaptic cytomatrix protein
(PCLO) expression was higher in parental cells, cyclin G2
(CCNG2) expression was higher in resistant cells, and
transducer of ERBB2, 1 (TOB1) expression was higher in
parental cells, while cyclin E2 (CCNE2) was down-
regulated in resistant cells and inhibin, beta E (INHBE)
was down-regulated in parental cells. These data indicate
that regardless of sensitivity, most genes, with a few excep-
tions, respond with similar patterns in expression in the
presence of drug.
The full list of genes showing at least 1.5 fold change
in expression following drug treatment in either parental
or resistant cells can be found in Additional file 1: Table
S1. Interestingly, of these 894 genes (out of 13,951 total
genes), none of the genes had fold changes that were
expressed +/− 1.5 fold in opposing directions in parental
compared resistant cells (Additional file 1: Table S1).
Together, these results suggest that inhibition of XPO1
affects multiple downstream pathways involving hundreds
of genes. Moreover, drug exposure resulted in similar
patterns of gene expression changes in both parental and
resistant cells. However, the extent of the response in
parental cells was much stronger than that in the resistant
cells.
In an effort to validate the microarray data, a subset of
genes that were found to be up-regulated in both paren-
tal and resistant cells in response to drug treatment were
tested by real-time quantitative PCR (qPCR). For this
validation, HT1080 parental and resistant cells, as well
as primary normal keratinocytes (Neo-NHEK) and the
keratinocyte cell line HaCaT were tested in vitro, while
normal human leukocytes were isolated from donor
blood and tested ex vivo. Genes were selected for valid-
ation based on an arbitrary fold change cutoff of 2.5 and
those genes containing regulatory elements that are acti-
vated by TSPs such as p53 and FOXO were identified
(Table 7). qPCR analysis showed that all of the 19 genes
selected from the microarray data were up-regulated in
both parental and resistant HT1080 cells in response to
drug treatment, thus confirming the microarray results.
In both the parental and resistant HT1080 cells types,
genes were induced between 2- and 400-fold. Genes
such as solute carrier family 16, member 6 (SLC16A6),
solute carrier family 43 (amino acid system L trans-
porter) member 2 (SLC43A2), arrestin domain contain-
ing 3 (ARRDC3), nerve growth factor receptor (NGFR),
and heat shock 70 kDa protein 4-like (HSPA4L) were
highly up-regulated in all cell types in response to treat-
ment with SINE compounds, exemplifying the effect of
inhibiting XPO1 protein in both malignant and normal
cells. Many of these validated genes also contain XPO1
cargo transcription factor binding elements, supporting
the observation that inhibition of XPO1 by SINE com-
pounds forces nuclear retention of TSPs allowing them
to be functionally active in the nucleus and drive tran-
scription of their target genes.
Lastly, because p53 is a major tumor suppressor protein
whose function relies on its nuclear retention in response
to SINE compound treatment, we sought to interrogate
the microarray data for those genes whose expression is
known to be regulated (either positively or negatively) by
p53. Additional file 1: Table S2 lists all of the differentially
expressed genes present in Additional file 1: Table S1 that
have p53 regulatory elements (as determined by MetaCore
analysis, where “+” is positive, “-“is negative, and “?” is un-
certain regulation by p53) from resistant versus parental
cells post-treatment.
Together, these results demonstrate that resistant
HT1080 cells are not absolutely agnostic to SINE com-
pounds but rather have reduced sensitivity, and that
when resistance is conferred multiple pathways are altered
thereby providing suggestions for specific pathways that
can be targeted for future combination studies with seli-
nexor treatment.
Discussion
Many cancers develop resistance to treatment, rendering
the therapy ineffective and resulting in the onset of a re-
fractory disease. Although resistance to selinexor in the
(See figure on previous page.)
Fig. 4 Microarray quadrant analysis for differentially expressed genes in parental versus resistant SINE compound-treated cells. Untreated parental
cells were compared to treated parental cells (x-axis) while untreated resistant cells were compared to treated resistant cells (y-axis) and genes
that were 1.5 fold up- and down- regulated in each of the SINE compound treated cell lines were plotted. a Fold change in mRNA expression
following KPT-185 treatment of apoptosis and autophagy-related genes. NGFR induction was similar in both cell lines, while TP53INP1 and BIRC3
induction was stronger in parental cells; EGR-1 was induced exclusively in resistant cells while IL1B was down-regulated only in parental cells. b Fold
change in mRNA expression following KPT-185 treatment of proliferation-related genes. EDN-1 induction was stronger in resistant cells; BTG2 induction
was stronger in parental cells; KITLG was exclusively down-regulated in resistant cells. c Fold change in mRNA expression following KPT-185 treatment
of cell-cycle and cytoskeleton-related genes. PCLO induction was stronger in parental cells; CCNG2 induction was stronger in resistant cells; TOB1
induction was stronger in parental cells; CCNE2 and INHBE were exclusively down-regulated in resistant and parental cells, respectively. Black line
represents perfect correlation as reference
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clinic has not been reported, we sought to predict the
characteristics of potential SINE resistance mechanisms
by creating a SINE compound-resistant cell line from
parental fibrosarcoma cells that are sensitive to SINE
compound treatment. To identify methods for overcom-
ing resistance, resistant and parental sensitive cells were
Table 5 MetaCore analysis of fold changes in expression of proliferation-related genes in SINE compound-resistant versus parental
cells post-treatment
FDR = Benjamini-Hochberg False Discovery Rate. Red = positive, blue = negative, color intensity corresponds to fold change magnitude
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Table 6 MetaCore analysis of fold changes in expression of cell cycle and cytoskeleton-related genes in SINE compound-resistant
versus parental cells post-treatment
FDR = Benjamini-Hochberg False Discovery Rate. Red = positive, blue = negative, color intensity corresponds to fold change magnitude
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Table 7 RT-PCR verification of microarray gene expression and identifcation of XPO1 cargoes containing a TSP 5’ regulatory element(s)
















Fold Induction RT-PCR Fold Induction RT-PCR
SLC16A6 4.04 7.05 10X 14X 3X (24hrs) 10X (4hrs) 30X (4hrs) FOXO1
SLC16A9 4.45 7.7 4X 16X 3.5X (4hrs) No induction No expression NF-AT
BIRC3 2.99 1.65 3X 2.5X 3X (24hrs) 2X (24hrs) No Induction p53
SLC43A2 6.41 6.99 12X 16X 6X 4X 4.5X (4hrs) FOXO1
GNG2 2.69 1.91 3X 2.5X 4X (4hrs) 20X No Induction
ACER2 2.71 2.01 4X 2.5X 3.5X (24hrs) No Induction 2.5X (24hrs) p53
BTG2 3.19 1.86 3.5X 2X 2.5X (24hrs) No Induction No Induction p53, FOXO1
RRAGD 2.76 2.55 3X 3X 2 X No expression 7X AP-1
NPY1R 2.97 1.77 4X 3.5X 3X (4hrs) No Induction 3X (24hrs) p53, NF-AT
SLC44A2 5.33 3.97 8X 9X 2X No Induction No Induction
PLCD4 3.03 3.43 13.5X 9X 2.5X (4hrs) No Induction No expression p53, FOXO1, AP-1
FAS 2.68 1.99 2.5X 2.5X No Induction No Induction No Induction p53, AP-1
ARRDC3 4.05 4.3 5.5X 7X 8X (24hrs) 5X (4hrs) 5X FOXO1,3
NGFR 5.18 5.92 400X 70X 43X (4hrs) 5.5X (4hrs) 100X (4hrs) p53, FOXO4, NF-AT
Tp53INP 3.8 2.84 6X 3X 5X (24hrs) 5.5X (24hrs) No Induction
PCLO 7.33 6.24 30X 25X 9X 6X (4hrs) No Induction FOXO1,3, NF-AT, AP-1
HSPA4L 4.38 3.32 7X 5X 2X (24hrs) 2X (4hrs) 27X (24hrs) AP-1
STK32A 8.92 8.4 90X 10X No expression No expression No Induction












compared pre-treatment and post-treatment to identify
mechanisms leading to the resistant phenotype as well
as investigate their differential response to SINE com-
pound treatment.
The extensive period of time required to achieve re-
sistance speaks to the fact that SINE compounds are an
effective, robust therapy for killing cancer cells. Develop-
ment of resistance to the SINE compound KPT-185
required 10 months of continuous exposure in vitro. In
comparison, it took 3 months to develop resistance to the
tyrokinase inhibitor STI571 by chronic myelogenous
leukemia cell lines [58], 6 months to develop resistance to
taxol in the human ovarian cancer cell line A2780 [59],
and 12 weeks to develop resistance to the HDAC inhibitor
valproic acid by renal cell carcinoma Caki-1 cells [60]. Al-
though resistant cells were selected by treatment with
KPT-185, these cells were also resistant to KPT-330 (seli-
nexor) as well as to LMB, indicating conservation of the
mechanism(s) of resistance across different inhibitors of
XPO1.
A characteristic feature of SINE compound treatment
on cells both in vitro and in vivo is the nuclear retention
of key XPO1 cargoes [reviewed in [54]]. Although certain
cargoes are detected in the nuclei of SINE compound-
resistant cells treated with KPT-185, nuclear accumulation
was greatly reduced compared to parental cells. It is likely
that nuclear retention of XPO1 cargoes would be en-
hanced if resistant cells were treated with higher concen-
trations of KPT-185 because of the changes observed in
the levels of proteins by immunoblot (Fig. 3). In agree-
ment with previously published studies, the XPO1 inhib-
ition in parental cells lead to increased protein levels of
p53 [9, 12, 42, 44, 45, 50], which corresponded with in-
creased gene expression of tumor protein p53 inducible
nuclear protein 1 (TP53INP) by both parental and resist-
ant cells in the microarray (see Additional file 1: Table S1).
Increase in the protein level of the p53 transcriptional tar-
get p21 [13, 40, 48] also corresponded with increased gene
expression of cyclin-dependent kinase inhibitor 1A (p21,
Cip1) (CDKN1A) by parental cells in the microarray (see
Additional file 1: Table S1), whereas a decrease in p-pRb
[42] and Mcl-1 [12, 31, 46] proteins were observed in both
cell types. That the expression of the above proteins was
only affected to the same extent in resistant compared to
parental cells when the resistant cells were treated with 3
times more drug than parental cells (see Fig. 3) suggests
that resistant cells are not strictly “resistant” to SINE com-
pounds but rather are less sensitive.
Evaluation of the effects of SINE compound treatment
on the cell cycle as determined by FACS analysis showed
both similarities as well as a distinct difference between
parental and resistant cells. SINE compound treatment in-
duced G1 arrest with a concomitant decrease in S phase
in both parental and resistant cells, which has also been
reported in the AML cell lines MV4-11, OCI-AML3, and
MOLM-13 [37], and in the kidney cancer cell lines ACHN
and 786-O [7]. However, SINE compound treatment only
led to arrest in the G2/M phase of parental cells while
having no effect on the G2/M phase of resistant cells. This
suggests that parental cells arrest in G1 and those cells
that were in S phase accumulate in G2/M, whereas resist-
ant cells that exit S phase are able to cycle through G2/M
and accumulate in G1, resulting in the higher percentage
of resistant cells in G1 at each day post treatment com-
pared to parental cells. The observation that S phase is
not completely lost in resistant cells post SINE treat-
ment is indicative of their ability to continue to prolif-
erate in the presence of drug as was observed in the
clonal growth assay. The observation that SINE com-
pound treatment arrested both parental and resistant
cells in G1 also correlated with gene expression data
from the microarray results. The observation that a
large fraction of resistant cells are arrested in G1 corre-
sponded with a greater reduction in the expression of
three genes important for G1-S transition, CCNE1,
CCNE2, and CDC25A [reviewed in [61, 62]] and for S
phase initiation, CDC6 [reviewed in [63]] in resistant
compared to parental SINE compound treated cells.
The microarray results suggest that acquired resist-
ance to SINE compounds is associated with combined
modulation of adhesion-related genes, amplification of
inflammation pathways, up-regulation of anti-apoptotic
machinery coupled to down-regulation of pro-apoptotic
pathways, as well as activation of immune evasion
mechanisms. The comparison of the expression profile
of adhesion pathway genes in untreated parental to re-
sistant cells indicates that resistant cells have a more
aggressive phenotype, which is typically characterized
by increased invasion, metastatic ability, and resistance
to therapy [64]. For example, the expression of HAS2,
OPN, ITGB8, and MMP9 was higher in resistant cells.
HAS2 (hyaluronin synthase 2) produces HA (hyalur-
onic acid) and its expression is significantly correlated
with tumorigenicity and tumor progression in several
cancers [65]; OPN (osteopontin) is a secretory adhesive
protein overexpressed in a variety of cancers and its
overexpression is correlated with poor prognosis [66];
ITGB8 (integrin beta 8) overexpression correlates with
increased invasiveness [67]; and MMP9 (matrix metal-
loproteinase 9) enhances the invasion and metastasis of
tumor cells [68] and its induction is a feature of acti-
vated fibroblasts, myofibroblasts [69] (also see changes
in smooth muscle actin below). These changes in gene
expression are also in agreement with phenotypic
changes of resistant cells that were observed in culture,
with increased adhesion to tissue culture dishes in
comparison with parental cells (length of exposure to
trypsin, not shown). In further support of changes in
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adhesion-related genes, significant down-regulation of
NID2 (nidogen 2) was observed in resistant cells. Re-
cent studies suggest that reduced expression of this
gene correlates with higher rate of metastasis [70, 71]
further supporting the theory that resistant cells have a
more aggressive phenotype than parental cells.
The observation that resistant cells are more difficult
to kill than parental cells, as evidenced by increased
SINE compound IC50 values, persistent growth in the
clonal assay, and less cleaved PARP and Caspase 3 pro-
teins in resistant compared to parental cells, is further
supported by changes in gene expression in the group of
apoptosis related genes. Resistant cells induce the tran-
scription of CLU (clusterin) and down-regulate the ex-
pression of PLAGL1 (pleiomorphic adenoma gene-like
1). CLU is overexpressed in several cancers and has been
shown to inhibit apoptosis by interfering with Bax activa-
tion in mitochondria [72], while PLAGL1 is a tumor sup-
pressor protein, which concurrently induces apoptosis and
cell cycle arrest [73].
From the pro-inflammatory genes, Chemokine C-C
motif ligand 2 (CCL2) was the most up-regulated in re-
sistant versus parental cells, followed by another pro-
inflammatory protein, TREM1 (triggering receptor
expressed on myeloid cells 1). CCL2 has been impli-
cated in promoting breast cancer metastasis [74] as well
as prostate cancer growth [75] while TREM1 expression
in hepatic satellite cells negatively correlated with disease
outcome and its expression was related to aggressive
tumor behavior [76]. The class II major histocompatibility
complex determinant HLA-DPB1 was down-regulated in
resistant cells. Failure to express Class I and/or Class II
MHC determinants is a common feature of the majority
of human prostatic carcinoma cells and may represent an
immune evasion mechanism promoting tumor survival
and metastasis [77].
Although expression changes for most genes were
similar in parental and resistant cells in response to drug
treatment, the extent of the change was generally stron-
ger in parental cells. For example, NPY1R was upregu-
lated 2.97 fold after drug treatment in parental cells,
while only 1.77 fold in resistant cells. A few studies sup-
port an anti-proliferative and possibly pro-apoptotic role
for NPY1R [78, 79], but this function requires activation
by NPY and it is not clear whether a pure transcriptional
event translates to an anti-proliferative function in-vitro.
ID2 (inhibitor of DNA binding 2, dominant negative
helix-loop-helix binding protein), which was found to be
pro-apoptotic in osteosarcoma cells [80], was exclusively
induced in parental cells. Several anti-apoptotic genes
were exclusively down-regulated in parental cells. These
include VEGFA, IL1B (interleukin 1 beta), and XBP1 (X-
box binding protein 1). Inhibition of VEGFA production
in tumor cells has previously been reported to induce
apoptosis in-vitro [81] and a reduction in levels of VEGFA
also suggests a potential anti-angiogenic effect of SINE
compound treatment in vivo. Another notable difference
is in the expression of EGR1 (early growth response 1), in-
duced exclusively in resistant cells. EGR-1 may act as ei-
ther a tumor promoter or suppressor, depending on the
type of tumor [82]. In HT-1080 fibrosarcoma cells, EGR-1
was found to suppress cell growth by activating TGF-beta
1 [83] and in a recent study of synovial sarcoma, it was
found to mediate cell death induced by HDAC inhibitor
through activation of PTEN [84]. The up-regulation EGR-
1 expression may thus represent an anti-proliferative
mechanism unique to SINE compound activity in resistant
HT-1080 cells.
Several changes were also observed in the proliferation-
related response to drug treatment. As expected, a num-
ber of anti-proliferative genes were more strongly induced
in parental cells, including BTG2 (BTG family, member
2), TOB1 (transducer of ERBB2, 1), SESN1 (sestrin 1), and
GNG2 (guanine nucleotide binding protein). In contrast,
EDN1 (endothelin 1), which is a known pro-survival pro-
tein in ovarian carcinoma [85], was more strongly induced
in resistant cells, in line with a pro-survival response.
Finally, the transcriptional response of genes related to
cell-cycle and cytoskeleton expression changes was largely
similar in parental and resistant cells, with most of the
genes mildly down-regulated. A few notable differences
include p21, induced only in parental cells, which could
be related to the higher expression of PLAGL1 in resistant
cells [86], CCNE1 (cyclin E1), CCNE2 (cyclin E2) and
CDC25A,which are exclusively down-regulated in resist-
ant cells, HDAC9 which is up-regulated only in resistant
cells, and ACTA2 (α smooth muscle actin), which is
higher in resistant cells. HDAC9 was recently found to
promote angiogenesis [87] and increased expression of
ACTA2 is a hallmark of fibroblast transformation to myo-
fibroblasts [69]. While the latter is also in accord with the
increased expression of MMP9 by resistant HT1080 at
baseline, ACTA2 is also a direct transcriptional target of
the tumor suppressor p53 [88] so its role in the response
to SINE compounds is unclear and remains to be ex-
plored. These patterns of changes in gene expression indi-
cate that the response to SINE compound treatment
described above is mostly pro-apoptotic, anti-proliferative,
and cytostatic.
Validation of the microarray results provided many ex-
amples of genes that could be evaluated as potential bio-
markers to predict response to treatment with SINE
compounds. SLC16A6, SLC43A2, ARRDC3, NGFR, and
HSPA4L were all up-regulated in response to drug treat-
ment by all cell types tested including parental malignant,
resistant malignant, and normal cell lines, as well as nor-
mal leukocytes isolated from healthy human blood.
SLC16A6 functions as a proton-linked monocarboxylate
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transporter and was found to be significantly increased in
drug resistant ovarian cancer cell lines [89]. SLC43A2 is a
Na+-, Cl−-, and pH-independent high affinity transporter
of large neutral amino acids whose role in cancer has not
been determined [90]. Up-regulation of ARRDC3 would be
a beneficial effect of SINE compound treatment as it was
shown that its overexpression represses breast cancer cell
proliferation and does so by negatively regulating beta-4 in-
tegrin [91]. Depending on the context, NGFR expression
can either be oncogenic or tumor suppressive and recent
studies with colon cancer indicate it has anti-tumor activity
[92]. The role of the heat shock protein HSPA4L is unclear
but the gene was found to have a hypermethylated pro-
moter in leukemia cell lines [93]. Further studies are neces-
sary to determine the functional relevance of the up-
regulation of these genes in response to drug treatment.
Conclusions
In summary, resistance to SINE compounds generated in
HT1080 cells appears to be a reflection of reduced sensitiv-
ity of the overall system to XPO1 inhibition, and is not due
to mutation of the target, prevention of drug binding, or
drug efflux. Developed resistance is characterized by de-
creased potency of XPO1 inhibitors, altered cell cycle pro-
file and less forced nuclear retention of XPO1 cargo. By
evaluating global gene expression changes pre- and post-
treatment, we have developed a profile of gene alterations
relevant to SINE compound response and the development
of resistance. Components of this profile include 1) genes
that are altered when resistance is conferred in an originally
SINE compound sensitive cell type, 2) genes whose expres-
sion is altered in parental cells in response to drug treat-
ment, 3) genes whose expression is altered in resistant cells
in response to drug treatment, and 4) a menu of genes
whose expression is affected when XPO1 is inhibited in
both malignant and normal cells. Both the large number of
genes found, as well as the tendency for their expression to
trend in the same direction (up or down) in both parental
and resistant cells suggests that inhibiting XPO1 has a wide
effect on downstream pathways and that this effect is more
drastic in parental than resistant cells. Closer examination
of the pathways identified will be necessary to provide a ra-
tionale for testing inhibition of specific targets in combin-
ation with SINE compounds to enhance the activity of
SINE compound mono-therapy.
Additional file
Additional file 1: Table S1. MetaCore analysis of fold changes in
expression of all genes in SINE compound-resistant versus parental
cells post-treatment. FDR = Benjamini-Hochberg False Discovery Rate.
Red = positive, blue = negative, color intensity corresponds to fold
change magnitude. Table S2. MetaCore analysis of fold changes in
expression of genes with p53 regulatory elements in SINE compound-
resistant versus parental cells post-treatment. FDR = Benjamini-
Hochberg False Discovery Rate. In the p53 regulation column, “+”,
“-“and “?” correspond to positive, negative, and uncertain regulation
by p53, respectively. Red = positive, blue = negative, color intensity
corresponds to fold change magnitude. (XLSX 104 kb)
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